OBP-301

BIOLOGICAL6 trials

Sponsors

Oncolys BioPharma Inc, Toshihiko Doi, Syneos Health, Weill Medical College of Cornell University

Conditions

Advanced Solid TumorCarcinoma, HepatocellularEsophageal AdenocarcinomaEsophageal CancerGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaHead and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive DiseaseMelanoma Stage III

Phase 1

Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma

Oncolys BioPharma IncCarcinoma, Hepatocellular

Start: 2014-10-31End: 2021-04-30Target: 18Updated: 2018-08-20

Special Combination of OBP-301 and Pembrolizumab

CompletedNCT03172819

Toshihiko DoiAdvanced Solid Tumor

Start: 2017-10-01End: 2022-04-06Updated: 2022-09-28

A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer

Oncolys BioPharma IncEsophageal Cancer

Start: 2017-07-07End: 2019-06-30Target: 12Updated: 2018-09-26

Phase 2

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Syneos HealthMelanoma Stage III, Melanoma Stage Iv

Start: 2016-12-22End: 2021-10-31Updated: 2019-04-16

Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease

TerminatedNCT04685499

Weill Medical College of Cornell UniversityHead and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease

Start: 2021-05-03End: 2022-06-03Updated: 2023-01-11

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

RecruitingNCT06340711

Weill Medical College of Cornell UniversityEsophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

Start: 2024-04-25End: 2030-04-01Target: 27Updated: 2026-04-23

Related Papers

Abstract CT193: Final results from a phase I study to evaluate the safety and efficacy of a telomerase-specific oncolytic adenovirus (OBP-301) with pembrolizumab in patients with advanced solid tumors (EPOC1505)

Cancer Research2023-04-14

Safety and dose-escalation study of a targeted oncolytic adenovirus, suratadenoturev (OBP-301), in patients with refractory advanced liver cancer: Phase I clinical trial.

Journal of Clinical Oncology2022-01-192 citations

Abstract CT024: Early safety from an open label Phase I study to evaluate the safety and efficacy of a telomerase-specific oncolytic adenovirus (OBP-301) with pembrolizumab in patients with advanced solid tumors. (EPOC1505)

Cancer Research2019-07-01

Abstract CT024: Early safety from an open label Phase I study to evaluate the safety and efficacy of a telomerase-specific oncolytic adenovirus (OBP-301) with pembrolizumab in patients with advanced solid tumors. (EPOC1505)

Clinical Trials2019-07-01

An open label phase I study to evaluate the safety and efficacy of OBP-301 with pembrolizumab in patients with advanced solid tumors.

Journal of Clinical Oncology2018-05-202 citations